Corcept Therapeutics Incorporated
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph K. Belanoff
- Full Time Employees
- 730
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 101 Redwood Shores Parkway Redwood City CA United States 94065
- IPO Date
- Apr 14, 2004
- CIK
- 0001088856
- Website
- corcept.com
- Similar Companies
- Business
- Corcept Therapeutics Incorporated (Nasdaq: CORT) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes drugs modulating cortisol activity at the glucocorticoid receptor to treat severe metabolic, oncologic, psychiatric and endocrine disorders. The company markets Korlym (mifepristone), the first FDA-approved treatment for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery; Korlym is available through a limited network of specialty pharmacies with patient support programs including financial assistance. Corcept advances a pipeline of proprietary selective cortisol modulators, including relacorilant in Phase 3 for Cushing's syndrome (PDUFA target date December 30, 2025) and in Phase 3 ROSELLA trial combined with nab-paclitaxel for platinum-resistant ovarian cancer (PDUFA target date July 11, 2026), where it demonstrated improved progression-free and overall survival in October 2025 ASCO late-breaker data; nenocorilant in Phase 1b with nivolumab for solid tumors; and other candidates targeting antipsychotic-induced weight gain, NASH, triple-negative breast cancer, castration-resistant prostate cancer, endometrial cancer, cervical cancer and platinum-sensitive ovarian cancer post-PARP inhibitor progression. Founded in 1998 and headquartered in Redwood City, California, the company conducts operations primarily in the United States and pursues global regulatory submissions including in Europe. Recent developments include Q3 2025 revenue of $207.6 million versus $182.5 million in Q3 2024, lifted full-year 2025 revenue guidance, initiation of new BELLA trial arms for relacorilant plus nab-paclitaxel with bevacizumab in platinum-sensitive ovarian cancer and in endometrial cancer, a Phase 2 collaboration with Arcagy Research for relacorilant plus nab-paclitaxel in cervical cancer, an ongoing transition to a new specialty pharmacy for Korlym fulfillment, and expansion of over 30 studies across endocrinology, oncology, metabolism and neurology.
Company News
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock
Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co.
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Has Consensus Target Price of $138.17 According to Analysts
Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT)
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Corcept Announces Planned Leadership Transition
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $29,842.72 in Stock
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept Grows to Mid-Cap on Institutional Support
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
Corcept: Not Cheap, But Backed By Real Structural Growth
Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?